Literature DB >> 32667998

Strategies for Implementation Research to Investigate the Negative Pharmacokinetic Interaction Between Efavirenz and Dolutegravir.

Gene D Morse1.   

Abstract

Entities:  

Keywords:  dolutegravir; drug interaction; efavirenz; implementation research

Year:  2021        PMID： 32667998      PMCID： PMC8130025          DOI： 10.1093/cid/ciaa982

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  21 in total

1.  Clinical pharmacology becomes a specialty in South Africa.

Authors:  A Walubo; K I Barnes; E Kwizera; O Greeff; B Rosenkranz; G Maartens
Journal:  S Afr Med J       Date:  2013-01-09

2.  Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.

Authors:  S Nanzigu; J Eriksen; F Makumbi; S Lanke; M Mahindi; R Kiguba; O Beck; Q Ma; G D Morse; L L Gustafsson; P Waako
Journal:  HIV Med       Date:  2011-11-22       Impact factor: 3.180

3.  Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients.

Authors:  Jackson K Mukonzo; Allan Kengo; Bisaso Kutesa; Sarah Nanzigu; Anton Pohanka; Timothy D McHugh; Alimuddin Zumla; Eleni Aklillu
Journal:  Trans R Soc Trop Med Hyg       Date:  2020-02-07       Impact factor: 2.184

4.  The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in zimbabwe.

Authors:  Tinashe Mudzviti; Charles C Maponga; Star Khoza; Qing Ma; Gene D Morse
Journal:  AIDS Res Treat       Date:  2012-03-19

Review 5.  Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.

Authors:  Renée Dagenais; Kyle John Wilby; Hazem Elewa; Mary H H Ensom
Journal:  Drugs R D       Date:  2017-09

6.  Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study.

Authors:  Allan Buzibye; Joseph Musaazi; Amrei von Braun; Sarah Nanzigu; Christine Sekaggya-Wiltshire; Andrew Kambugu; Jan Fehr; Mohammed Lamorde; Ursula Gutteck; Daniel Muller; Stefanie Sowinski; Steven J Reynolds; Barbara Castelnuovo
Journal:  AIDS Res Ther       Date:  2019-12-06       Impact factor: 2.250

7.  Mentored postdoctoral training in Zimbabwe: A report on a successful collaborative effort.

Authors:  Danai T Zhou; Charles C Maponga; Munyaradzi Madhombiro; Admire Dube; Runyararo Mano; Albert Nyamhunga; Ian Machingura; Justen Manasa; James Hakim; Z Mike Chirenje; Tinashe Mudzviti; Charles Nhachi; Qing Ma; Robin DiFrancesco; Rangarirai Masanganise; Gene D Morse
Journal:  J Public Health Afr       Date:  2020-03-20

8.  Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.

Authors:  Eliford Ngaimisi; Abiy Habtewold; Omary Minzi; Eyasu Makonnen; Sabina Mugusi; Wondwossen Amogne; Getnet Yimer; Klaus-Dieter Riedel; Mohammed Janabi; Getachew Aderaye; Ferdinand Mugusi; Leif Bertilsson; Eleni Aklillu; Juergen Burhenne
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

9.  Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.

Authors:  Jackson K Mukonzo; Joel S Owen; Jasper Ogwal-Okeng; Ronald B Kuteesa; Sarah Nanzigu; Nelson Sewankambo; Lehana Thabane; Lars L Gustafsson; Colin Ross; Eleni Aklillu
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

10.  Is there a role of pharmacogenomics in Africa.

Authors:  A Matimba; M Dhoro; C Dandara
Journal:  Glob Health Epidemiol Genom       Date:  2016-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.